CPT code 88271 represents molecular cytogenetic testing using DNA probe methods, most commonly fluorescence in situ hybridization (FISH), to evaluate cells for genetic abnormalities such as chromosomal rearrangements, amplifications, or deletions. This test informs diagnosis, prognosis, and treatment planning across oncology, hematology, and genetic disease management, making it a critical laboratory service in modern precision medicine.

Key payers in the national discussion include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns and benchmarking context for these major payers. Readers will find a concise clinical context for the test, typical sites of service, common billing considerations, and an overview of what benchmarks and policy topics are relevant to reimbursement and utilization.

The report provides benchmarks for utilization and reimbursement where available, highlights recent policy updates that affect molecular cytogenetic testing, and summarizes clinical situations driving demand for 88271 services. Data not provided in the input — such as specific payer rates, ICD-10 mappings, and associated taxonomies — are noted as unavailable. The content is intended for national audiences including laboratory administrators, billing professionals, and policy analysts seeking an up-to-date briefing on CPT code 88271 and its role in clinical diagnostics.